56:04
EULAR 2026 Rheumatology Round Up
RheumNow
9:02
Efficacy and Safety of Ianalumab in Sjogren's Disease
3:38
CAR-T For Rheumatoid Arthritis
48:46
Psoriatic Arthritis Topic Panel: EULAR 2026
39:35
Day 4 Recap: EULAR 2026
54:26
Rheumatoid Arthritis Topic Panel: EULAR 2026
11:28
EULAR 2026 Recommendations: Immunization
6:36
Making Methotrexate More Effective
29:03
Do You Zoster Vaccinate? (6.19.2026)
36:39
Day 1 + 2 Recap: EULAR 2026
6:35
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
4:51
Are we failing in the treatment of RA-ILD?
8:06
Guselkumab Delivers Across the PsA Disease Spectrum: APEX Trial
8:50
2026 EULAR Preview
47:29
Day 3 Recap: EULAR 2026
8:45
New axSpA Criteria: Who gets left out?
38:04
CAR-T Topic Panel: EULAR 2026
2:42
Gout and ULT Withdrawal -- The GO TEST FINALE Trial
17:44
DERM on RheumNow (June 2026)
10:24
Treat to Target Works in Elderly Onset RA
19:35
MACE and Safety Profile of bDMARDs/JAKis in axSpA and PsA
5:19
Obexelimab in IgG4-Related Disease: INDIGO Trial
2:05
SLE Pipeline of New Therapies
3:19
‘Strong’ Treatment Predictions in Inflammatory Myositis
5:47
Baricitinib for Remission Induction and Glucocorticoid Sparing in New-Onset PMR
10:41
JAKi VTE Risk: Does Aspirin, NSAID, or DOAC Use Matter?
4:17
Transition from Psoriasis to Psoriatic Arthritis
5:55
Combination Therapy: Off the Shelf Allogenic NK and Rituximab in Rheumatic Disease
4:52
Improving Referrals for Inflammatory Arthritis
5:27
Tissue B Cell Depletion with Obinutuzumab in SLE
4:00
BE BOLD: Going Where No PsA Trial Has Gone Before
2:01
Renal Biopsies in SLE
8:37
Tofacitinib in Early AxSpA
7:59
What Happens when CAR-T Fails Managing Disease Recurrence
5:05
Imaging in Subclinical Psoriatic Arthritis
9:41
Another Way to Leverage NK Cells to Kill B Cells, This Time Without CARs
7:40
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
5:08
Anifrolumab Scores in Sjogren's Phase 2 Trial
4:53
Management of Relapses After CAR-T Therapy in SLE, SSc and IIM
5:44
Breaking the IgG Cycle: Efficacy and Safety of Nipocalimab in SLE
4:56
PsA Potpourri: Probiotics & Head-to-Head Data
2:38
Debate: Combination Therapies for Inflammatory Arthritis?
8:10
This Is a Woman’s World: Women's Health in Rheumatic Disease
6:59
How Many CAR-Ts Do We Need to Test Drive?
2:48
Combination Biologics in PsA: MRI Findings from AFFINITY
2:11
Treat to Target in SLE
3:49
Virtual Biopsy in Cutaneous Lupus
2:59
Certolizumab in APS Pregnancies: Is the Benefit Real or a Cohort Effect?
11:49
The North American Expert Consensus on ASCVD Screening in Lupus Nephritis
3:32
The AFFINITY Study: Combination Treatment in PsA
4:18
Gecacitinib Pan-JAK inhibitor in Radiographic axSpA
4:07
Vaccination strategies for the rheumatologist
4:25
When Patients with RA Choose Their Treatment, Outcomes Are Better — Here's the Data
2:14
BMI Outranks Treatment in PsA Outcomes?
4:09
Beyond BMI: Altered Body Composition in Rheumatoid Arthritis
Why PROMS Matter in the Care of People with Lupus
Can AI Predict Progression to RA?
3:08
Dietary Interventions in PsA
6:15
Can We Stop PsA Before it Starts?
5:11
Long-term Cancer Risk with Targeted Therapy in SpA
3:24
Combination Therapy in SpA
5:34
The Case for Dual Pathway Blockade in Refractory PsA
5:06
AI vs. Google: Who Answers Your Patients' Questions Best?
4:15
The ULT-imate Question: Continue or Discontinue?
5:16
Synovial Biopsy–Guided Therapy Improves Clinical Outcomes in PsA
3:58
HPV Vaccination in Rheumatic Diseases
Switch or Cycle? Results from the ROC-SpA Study
5:02
Digital Patient Education in RA
